Isosorbide mononitrate-long-acting

Drug Profile

Isosorbide mononitrate-long-acting

Alternative Names: Elantan-LA; Elantan-long

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Schwarz Pharma
  • Developer Somedico
  • Class Heart failure therapies; Ischaemic heart disorder therapies; Organic nitrates; Small molecules; Sugar alcohols; Vasodilators
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Angina pectoris

Most Recent Events

  • 01 Feb 2016 Elantan® licensed to Meru Labs in Europe
  • 01 Feb 2016 UCB and Meru Labs sign an agreement for the rights of Elantan® in Europe and select other countries
  • 10 Feb 2014 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top